Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science tools and service providers, announced this past week their “all-star” list of advisors who possess domain experience and a proven record of success in the life science industry. Based in Englewood Cliffs, New Jersey the fund touts the deep technical knowledge of each advisor and their understanding of important industry trends.
“The team of advisors will bring insights on best practices and operational excellence needed for early stage companies. They are also well aware of all the key players likely for exiting to and how innovative technologies can fill gaps in their portfolios. This will ensure that companies which are highly likely to succeed are brought into the fund and will be best positioned to exit with maximum returns,” commented General Partner Daniella Kranjac in their press statement.
The addition of these advisors is expected to strengthen Dynamk’s mission to ease the way for startups that have disruptive technologies and services to gain the necessary capital that takes them to the next phase. Dynamk’s partners drew upon their network of fellow entrepreneurs, industry thought leaders and disrupters to identify the best candidates for the team of advisors who will help form sound strategic decisions to achieve the highest returns for investors.
The newly appointed advisors are:
- Kevin Bailey, PhD.; Former VP, Process Development and Preclinical Manufacturing, Regeneron.
- Barry Buckland, PhD.; CEO, BiologicB, LLC and former VP, Bioprocess R&D, Merck and Co., Inc.
- Anthony Maddaluna; Former President, Pfizer Global Supply. Anthony
- Gustavo Mahler, PhD.; CEO, CMC Biologics / AGC Asahi Glass.
“Dynamk Capital has the rare opportunity to help accelerate research, development and manufacturing in the biopharma industry by identifying companies with disruptive new technologies and facilitating getting them into the hands of those who will bring new products and hope to patients,” Kevin Bailey commented.
